We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

84 hedge funds and large institutions have $52.6M invested in CytomX Therapeutics in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 24

14% less funds holding

Funds holding: 98 → 84 (-14)

14.62% less ownership

Funds ownership: 69.65% → 55.03% (-15%)

34% less capital invested

Capital invested by funds: $79.5M → $52.6M (-$26.9M)

56% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 25

Holders
84
Holders Change
-14
Holders Change %
-14.29%
% of All Funds
1.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
23
Reduced
24
Closed
25
Calls
$30K
Puts
–
Net Calls
+$30K
Net Calls Change
-$7K

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$3.76M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$1.64M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.25M
4
BI
BVF Inc
California
+$1.22M
5
Renaissance Technologies
Renaissance Technologies
New York
+$541K

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$5.21M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$5.03M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.66M
4
CS
Candriam SCA
Luxembourg
-$3.03M
5
Millennium Management
Millennium Management
New York
-$1.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$9.56M +$1.22M +792,101 +14%
Vanguard Group
2
Vanguard Group
Pennsylvania
$6.58M -$832K -540,426 -11%
TCM
3
Tang Capital Management
California
$5.08M +$3.76M +2,445,327 +232%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$3.85M +$1.25M +814,350 +44%
RCMNY
5
Rubric Capital Management (New York)
New York
$3.49M – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$2.62M +$541K +351,339 +24%
BlackRock
7
BlackRock
New York
$2.61M -$41.9K -27,228 -1%
LCM
8
Laurion Capital Management
New York
$1.84M – – –
PIM
9
Platinum Investment Management
Australia
$1.78M – – –
Jacobs Levy Equity Management
10
Jacobs Levy Equity Management
New Jersey
$1.59M +$305K +197,869 +22%
Assenagon Asset Management
11
Assenagon Asset Management
Luxembourg
$1.54M +$1.64M +1,065,392 New
NM
12
Newtyn Management
New York
$1.16M -$421K -273,400 -25%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$1.02M -$2.52K -1,637 -0.2%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$851K +$6.75K +4,386 +0.8%
OMC
15
Oasis Management Company
Cayman Islands
$784K – – –
Millennium Management
16
Millennium Management
New York
$772K -$1.4M -909,219 -63%
Two Sigma Advisers
17
Two Sigma Advisers
New York
$765K +$216K +140,400 +36%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$710K +$373K +242,153 +98%
Two Sigma Investments
19
Two Sigma Investments
New York
$519K +$92.5K +60,077 +20%
FAM
20
Formidable Asset Management
Ohio
$451K +$159K +103,543 +50%
TI
21
Tidal Investments
Wisconsin
$451K +$159K +103,543 +50%
E
22
Ergoteles
New York
$405K -$59.9K -38,944 -12%
AA
23
AlphaCentric Advisors
Puerto Rico
$373K +$396K +257,500 New
State Street
24
State Street
Massachusetts
$325K – – –
Connor, Clark & Lunn Investment Management (CC&L)
25
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$306K +$5.58K +3,628 +2%
1
2 3 4 5

CTMX Hedge Fund Activity: Q3 2022 in Review

84 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2022, worth a combined $52.6M — down 34% from $79.5M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of CTMX and 11 opened new positions — a net loss of 14 holders — while 24 trimmed existing stakes and 23 added.

The largest buyer was Tang Capital Management, adding an estimated $3.76M. The largest seller was RTW Investments, exiting entirely with an estimated $5.21M sold.

  • 84 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2022, down from 98 in Q2 2022.
  • Funds reported $52.6M of CytomX Therapeutics stock for Q3 2022, down 34% quarter-over-quarter.
  • 11 funds opened new CytomX Therapeutics positions in Q3 2022 and 25 closed out, a net change of -14 holders.
  • The largest CytomX Therapeutics buyer in Q3 2022 was Tang Capital Management, an estimated $3.76M added.
  • The largest CytomX Therapeutics seller in Q3 2022 was RTW Investments, an estimated $5.21M sold.

Based on aggregated 13F filings for Q3 2022.